AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11689738
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (20 g x d(‐1) for 5 days, then 5 g x d(‐1) for 5 days)
Trial: 11689738
Drug: Placebo (cornstarch,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cornstarch, same dosage regimen as Cr group)
Trial: 31218889
Drug: Run Zao
RxNorm normalized name: Zaocys dhumnades preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run Zao Zhi Yang capsule (RZZYC)
Trial: 31218889
Drug: Run Zao
RxNorm normalized name: Zaocys dhumnades preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Run Zao Zhi Yang capsule (RZZYC) and Placebo
Trial: 29192639
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg ropivacaine 1%
Trial: 29192639
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ropivacaine 1%
Trial: 29192639
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg ropivacaine 1%
Trial: 26562074
Drug: PEMF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEMF treatment (MAGCELL ARTHRO device), delivered a sinusoidal magnetic field of 4-12 Hz, magnetic flux density of 105 mT, treatment twice a day for 5 min over 18 days.
Trial: 26562074
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (placebo device)
Trial: 26562074
Drug: PEMF treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEMF treatment
Trial: 23415013
Drug: Clopidogrel alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel alone (double therapy)
Trial: 23415013
Drug: Clopidogrel plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel plus aspirin (triple therapy)
Trial: 30879003
Drug: AZD1981 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD1981 40 mg TID
Trial: 29299989
Drug: Curcumin 1000mg
RxNorm normalized name: Radiance Platinum Turmeric Curcumin 1000mg Capsule
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin 1000mg with 10mg of piperine daily
Trial: 27195662
Drug: Best contemporary
RxNorm normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best contemporary metallic drug-eluting stents (DES)
Trial: 24843205
Drug: G-Bone® (modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-Bone® (modified hydroxyapatite)
Trial: 17965442
Drug: C5aR-antagonist AcF-(OpdChaWR)
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: C5aR-antagonist AcF-(OpdChaWR) (PMX53)
Trial: 11753768
Drug: Passive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Passive treatment or no treatment
Trial: 9586884
Drug: Standard-dose cranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose cranial irradiation (SRT) of 36 Gy
Trial: 9586884
Drug: Reduced-dose cranial
RxNorm normalized name: geranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reduced-dose cranial irradiation (RRT) of 23.4 Gy
Trial: 2645441
Drug: Saphenous vein
RxNorm normalized name: Sus scrofa vein preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saphenous vein patch closure (n = 62)
Trial: 25809413
Drug: Prednisone at
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone at 0.75 mg/kg/day
Trial: 8750372
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of losartan 50 mg and hydrochlorothiazide 12.5 mg
Trial: 23496265
Drug: Maximum dose
RxNorm normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maximum dose of losartan (100 mg)
Trial: 19457937
Drug: ITP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ITP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2, paclitaxel 175 mg/m² on day 1)
Trial: 19457937
Drug: IP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IP regimen (ifosfamide 1.5 g/m² daily on days 1-3, cisplatin 70 mg/m² on day 2)
Trial: 16393594
Drug: Single one‐pass
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single one‐pass pulsed dye laser treatment (595 nm, 7 J/cm2 fluence, 7 mm spot size, 1.5‐millisecond pulse duration, 30‐millisecond spray, 20‐millisecond delay of dynamic cooling) at the time of suture removal (2 weeks after excision)
Trial: 16393594
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no treatment with laser)
Trial: 3158674
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg bid
Trial: 29333721
Drug: 60 g·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g·h‐1 (LG)
Trial: 29333721
Drug: 75 g·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g·h‐1 (HG)
Trial: 29333721
Drug: 90 g·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g·h‐1 (LGF)
Trial: 29333721
Drug: 112.5 g·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 112.5 g·h‐1 (HGF)
Trial: 29333721
Drug: 90 g·h‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 g·h‐1 glucose-fructose ingestion
Trial: 17574461
Drug: Zonisamide (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zonisamide (mean maintenance dosage 7.7 mg/kg/day, range: 4-16 mg/kg/day)
Trial: 12502672
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg daily
Trial: 21309844
Drug: Candesartan 32
RxNorm normalized name: candesartan 32 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 32 mg daily
Trial: 10190650
Drug: Salbutamol (beta2-adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (beta2-adrenoceptor partial agonist)
Trial: 10190650
Drug: ICI 118,551
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICI 118,551 (beta2-adrenoceptor antagonist)
Trial: 1979207
Drug: Levocabastine eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocabastine eye drops (0.5 mg/ml solution)
Trial: 23380515
Drug: High tidal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High tidal volume (Hi-TV) of 10 mL/kg, rate of 7 breaths/min, zero positive end-expiratory pressure
Trial: 23380515
Drug: Low tidal
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low tidal volume (Lo-TV) of 5 mL/kg, rate of 14 breaths/min, 5 cmH2O positive end-expiratory pressure
Trial: 21317598
Drug: Buprenorphine/naloxone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine/naloxone treatment integrated with HIV care
Trial: 11605710
Drug: Anthroposophic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthroposophic therapy
Trial: 11605710
Drug: Conventional cancer
RxNorm normalized name: Cancer/testis antigen 1
DrugBank: Cancer/testis antigen 1 (DB19291)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional cancer treatment
Trial: 9526967
Drug: Chlordiazepoxide (CDP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (CDP, Librium) 5 mg
Trial: 9526967
Drug: Chlordiazepoxide (CDP,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlordiazepoxide (CDP, Librium) 20 mg
Trial: 7510813
Drug: Lenograstim 5
RxNorm normalized name: LENOGRASTIM
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenograstim 5 micrograms/kg per day by 30-min infusion for 28 days or until neutrophil recovery
Trial: 2530384
Drug: h-alpha ANP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: h-alpha ANP infusion
Trial: 1234013
Drug: Intravenous salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous salbutamol (300 mug cumulative dose in three injections over 45 min)
Trial: 6795701
Drug: Higher dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dosage of ftorafur (2 g/m2/day X 5 days)
Trial: 6795701
Drug: 5‐FU combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU combination chemotherapy
Trial: 29346597
Drug: Exenatide 10
RxNorm normalized name: EXENATIDE 10MCG/DOSE 2.4ML 60D PEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exenatide 10 μg twice a day for 12 weeks
Trial: 24290606
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (3 g/d) and kinako (29.14 g/d)
Trial: 24290606
Drug: Kinako (29.14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinako (29.14 g/d)
Trial: 17625977
Drug: 10% solution
RxNorm normalized name: Mucomyst 10% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% solution of 15 g fructose
Trial: 17625977
Drug: 10% solution
RxNorm normalized name: Mucomyst 10% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% solution of 25 g fructose
Trial: 17625977
Drug: 10% solution
RxNorm normalized name: Mucomyst 10% Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10% solution of 50 g fructose
Trial: 17625977
Drug: 33% solution
RxNorm normalized name: Dextrose 5%, Sodium Chloride 0.33% Solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33% solution of 50 g fructose
Trial: 17625977
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of doses
Trial: 15989703
Drug: Granulocyte-macrophage colony-stimulating
RxNorm normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte-macrophage colony-stimulating factor (GM-CSF) at 250 mg/m2 per day, starting 24 hours after completion of chemotherapy and continuing up to 48 hours before the next cycle.
Trial: 15989703
Drug: Fludarabine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine and cyclophosphamide combination treatment.
Trial: 9833957
Drug: Nucleoside therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside therapy combined with a protease inhibitor (zidovudine + lamivudine + indinavir)
Trial: 9833957
Drug: Nucleoside therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nucleoside therapy alone
Trial: 353969
Drug: Trimipramine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimipramine (50 mg daily before bedtime)
Trial: 26447155
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) 1.8 g/d for 4 weeks
Trial: 21812266
Drug: Qumin Tongbi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Qumin Tongbi Nasal Spraying Agent (QTNSA)
Trial: 9250258
Drug: Nebulized heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulized heparin (20,000 units)
Trial: 9250258
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin (25 U/kg)
Trial: 8422173
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (surgical adjuvant chemotherapy with 12 mg/m2 of MMC on the day of operation, followed by 6 mg/m2 every 2 months for 6 times, and 800 mg/day of Futraful for one year)
Trial: 8422173
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (surgical adjuvant chemotherapy)
Trial: 8422173
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (no treatment)
Trial: 27673437
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment (Endoscopic sinus surgery)
Trial: 25601535
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal ranibizumab 0.3 mg
Trial: 23967634
Drug: Acupuncture +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture + medication (Shugan Jianwei Anshen Decoction + acupuncture daily at specific points)
Trial: 23967634
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (Deanxit, 1 tablet after getting up and after lunch)
Trial: 23967634
Drug: Chinese medicine
RxNorm normalized name: BUTYLENE GLYCOL 48 g in 240 mL CUTANEOUS TAPE [QIZHOUGUAI Chinese medicine patch]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese medicine (Shugan Jianwei Anshen Decoction, 1 dose a day)
Trial: 18641208
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea consumption (4 cups or 960 mL per day)
Trial: 14519794
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement capsule
Trial: 14519794
Drug: Antioxidant supplement
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant supplement tablet
Trial: 10896881
Drug: Loxiglumide (CCK-A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loxiglumide (CCK-A antagonist)
Trial: 1613678
Drug: Nimodipine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine (4 x 60 mg)
Trial: 31238972
Drug: Specific acupressure
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific acupressure (self-administered on five specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Trial: 31238972
Drug: Non-specific acupressure
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-specific acupressure (self-administered on five non-specific acupressure points, 1 min for each point, twice a day for 4 weeks)
Trial: 26218933
Drug: ESI (epidural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESI (epidural steroid injections)
Trial: 23834353
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of low molecular weight heparin (LMWH) and prednisolone
Trial: 23834353
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) alone
Trial: 31277722
Drug: No drugs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No drugs
Trial: 16888270
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA), 100 mg, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Trial: 16888270
Drug: Placebo, administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, administered as 14 daily suppositories starting within 12 hours after aneurysm treatment.
Trial: 25122038
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg, over 40 min)
Trial: 23822578
Drug: Proton pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton pump inhibitor‐based triple therapy
Trial: 21373300
Drug: Fascia-iliaca block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fascia-iliaca block with bupivacaine and parenteral saline injection (Group A)
Trial: 21373300
Drug: IV NSAID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV NSAID injection with fascia-iliaca block (Group B)
Trial: 18422393
Drug: Aspirin and
RxNorm normalized name: Aspirin and Caffeine Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and clopidogrel (dual antiplatelet therapy)
Trial: 18422393
Drug: Clopidogrel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel therapy duration
Trial: 18422393
Drug: Resistance to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistance to aspirin and clopidogrel
Trial: 16634993
Drug: Glucerna SR
RxNorm normalized name: GLUCERNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucerna SR 323 ml
Trial: 16634993
Drug: Ensure high
RxNorm normalized name: Ensure High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ensure high calcium 315 ml
Trial: 16634993
Drug: Glucose 75
RxNorm normalized name: glucose 75 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose 75 g
Trial: 10854861
Drug: LMWH (enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH (enoxaparin sodium, 40 mg daily) + low-dose aspirin (100 mg daily) in the first trimester (group 1, n=14)
Trial: 10854861
Drug: LMWH (enoxaparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LMWH (enoxaparin sodium, 40 mg daily) + low-dose aspirin (100 mg daily) in the second trimester (group 2, n=17)
Trial: 10854861
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin alone (group 3, n=15)
Trial: 8227478
Drug: 24 mg
RxNorm normalized name: uracil 224 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24 mg methylprednisolone (Medrol Tablets)
Trial: 8227478
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg methylprednisolone (Medrol Tablets)
Trial: 8227478
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg methylprednisolone (placebo)
Trial: 3541502
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg levothyroxine daily
Trial: 3541502
Drug: Routine thyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine thyroxine treatment
Trial: 31350962
Drug: Gonadotropin, GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin, GnRH antagonist, and GH from the eighth day of the cycle for about 5 days (n = 34)
Trial: 31350962
Drug: Gonadotropin, GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin, GnRH antagonist, and GH from the third day of the previous cycle for about 20 days (n = 32)
Trial: 31350962
Drug: Gonadotropin, GnRH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin, GnRH antagonist, and placebo from the eighth day of the cycle for about 5 days (n = 26)
Trial: 26933848
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg preoperatively)
Trial: 22545014
Drug: Polymerized collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polymerized collagen (2 mL, 6 intraarticular injections over 3 months)
Trial: 22545014
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 mL, 6 intraarticular injections over 3 months)
Trial: 20682030
Drug: Singing classes
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Singing classes (6-week course, twice weekly)
Trial: 1577045
Drug: Gallopamil 100
RxNorm normalized name: gallopamil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 100 mg b.i.d.
Trial: 1577045
Drug: Gallopamil 100
RxNorm normalized name: gallopamil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gallopamil 100 mg o.d.
Trial: 4063326
Drug: 20-50 g
RxNorm normalized name: immunoglobulin G
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-50 g Palatinit/d
Trial: 31733785
Drug: Lumbosacral orthosis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbosacral orthosis (LSO) with routine physical therapy
Trial: 30652982
Drug: Routine physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine physical therapy alone
Trial: 8541200
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline solution as placebo (n = 17)
Trial: 1791015
Drug: Aminophylline Tablets
RxNorm normalized name: Aminophylline Tablets
DrugBank: Aminophylline (DB01223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline Tablets
Trial: 27781255
Drug: Less than
RxNorm normalized name: IgA less than or equal to 50 mcg/mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Less than 3 months treatment group
Trial: 27781255
Drug: More than
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More than 3 months treatment group
Trial: 18065143
Drug: Interferon 1-b
RxNorm normalized name: Interferon gamma 1-b
DrugBank: Interferon gamma-1b (DB00033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon 1-b injections
Trial: 15741226
Drug: No maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No maintenance therapy (control)
Trial: 8746390
Drug: Non-drug treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-drug treatments
Trial: 8746390
Drug: Drugs (general)
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drugs (general)
Trial: 8746390
Drug: Benzodiazepines, antidepressants,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzodiazepines, antidepressants, and other substances
Trial: 761539
Drug: Proglumide (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proglumide (1200 mg daily)
Trial: 761539
Drug: Magnesium tricilicate
RxNorm normalized name: Magnesium Trisilicate
DrugBank: Magnesium trisilicate (DB09281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium tricilicate (1320 mg daily, active placebo)